Key Biodexa (Nasdaq: BDRX) AGM resolutions pass while others fail

Rhea-AI Filing Summary

Biodexa Pharmaceuticals PLC reported the results of its rescheduled Annual General Meeting held on June 30, 2026. Ordinary resolutions 1 through 7 were approved, with voting majorities of 94%, 73%, 92%, 81%, 81%, 91% and 94%, showing broad support for core business items.

Ordinary resolution 8 and special resolution 10 did not pass, and resolution 11 also failed because it was contingent on resolution 8. The company remains a clinical stage biopharmaceutical developer focused on gastrointestinal cancers and other diseases with unmet medical needs through programs such as eRapa, MTX240 and tolimidone.

Key Figures

Resolution 1 majority: 94% Resolution 2 majority: 73% Resolution 3 majority: 92% +4 more

7 metrics

Resolution 1 majority 94% Ordinary resolution 1 approval at June 30, 2026 AGM

Resolution 2 majority 73% Ordinary resolution 2 approval at June 30, 2026 AGM

Resolution 3 majority 92% Ordinary resolution 3 approval at June 30, 2026 AGM

Resolution 4 majority 81% Ordinary resolution 4 approval at June 30, 2026 AGM

Resolution 5 majority 81% Ordinary resolution 5 approval at June 30, 2026 AGM

Resolution 6 majority 91% Ordinary resolution 6 approval at June 30, 2026 AGM

Resolution 7 majority 94% Ordinary resolution 7 approval at June 30, 2026 AGM

Key Terms

Annual General Meeting, ordinary resolutions, special resolution, clinical stage biopharmaceutical, +2 more

6 terms

Annual General Meeting financial

"its re-scheduled Annual General Meeting held at 11.00 BST today"

ordinary resolutions financial

"ordinary resolutions 1 through 7 passed with majorities of 94%, 73%, 92%, 81%"

An ordinary resolution is a decision put to a company’s shareholders that is approved by a simple majority of votes cast, similar to a club decision passed when more than half the members agree. It covers routine matters such as electing directors, approving annual accounts or declaring dividends, and matters approved this way bind the company. Investors care because ordinary resolutions determine everyday governance and can change leadership, financial distributions, or policies with only majority support.

special resolution financial

"Ordinary resolution 8 and special resolution 10 failed to pass"

A special resolution is a formal shareholder vote that requires a higher-than-normal majority—typically around three-quarters—to approve major corporate changes, such as altering the company’s governing rules, selling the business, or winding it up. It matters to investors because it signals decisive, potentially value-altering actions that cannot be passed by a simple majority; think of it as needing extra votes to change the rules of a club, so minority interests are harder to override.

clinical stage biopharmaceutical financial

"a clinical stage biopharmaceutical company developing innovative products"

forward-looking statements regulatory

"Certain statements in this announcement may constitute “forward-looking statements”"

Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.

mTOR (mammalian Target Of Rapamycin) inhibitor medical

"Rapamycin is an mTOR (mammalian Target Of Rapamycin) inhibitor"

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 6-K: How Foreign Companies Report to the SEC →

Available on EDGAR 06/30/2026 - 04:30 PM Accepted by SEC EDGAR 06/30/2026 - 04:30 PM Learn about SEC filing dates

FAQ

What did Biodexa Pharmaceuticals (BDRX) announce in its June 2026 AGM update?

Biodexa Pharmaceuticals reported the voting outcomes of its rescheduled Annual General Meeting held on June 30, 2026. Ordinary resolutions 1 through 7 were approved with strong majorities, while certain later resolutions, including 8, 10 and contingent 11, did not pass.

Which Biodexa (BDRX) shareholder resolutions passed at the 2026 Annual General Meeting?

Ordinary resolutions 1 through 7 were approved at Biodexa’s 2026 Annual General Meeting. These resolutions received vote majorities of 94%, 73%, 92%, 81%, 81%, 91% and 94%, respectively, indicating substantial shareholder support for the company’s main AGM proposals.

Which Biodexa Pharmaceuticals (BDRX) resolutions failed at the June 2026 AGM?

Ordinary resolution 8 and special resolution 10 failed to pass at Biodexa’s June 30, 2026 Annual General Meeting. Resolution 11 also failed because it was explicitly contingent on the approval of resolution 8, so it could not proceed after that proposal was rejected.

What type of company is Biodexa Pharmaceuticals (BDRX) according to this filing?

Biodexa Pharmaceuticals is described as a clinical stage biopharmaceutical company. It is developing innovative products for diseases with unmet medical needs, including gastrointestinal cancers and type 1 diabetes, using drug candidates such as eRapa, MTX240 and tolimidone in various indications.

What are the main drug candidates in Biodexa’s (BDRX) development pipeline?

Biodexa’s pipeline includes eRapa, MTX240 and tolimidone. eRapa targets Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer, MTX240 targets Gastrointestinal Stromal Tumors, and tolimidone is being developed as an orally delivered Lyn kinase inhibitor for type 1 diabetes treatment.

Where is Biodexa Pharmaceuticals (BDRX) headquartered and listed?

Biodexa Pharmaceuticals’ headquarters and R&D facility are located in Cardiff, United Kingdom. The company’s shares are listed on Nasdaq under the ticker symbol BDRX, reflecting its status as a foreign private issuer accessing U.S. capital markets through SEC reporting.

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2026

Commission File Number: 001-37652

Biodexa Pharmaceuticals PLC
(Translation of registrant's name into English)

1 Caspian Point, Caspian Way, Cardiff, CF10 4DQ, United Kingdom
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

The information in the attached Exhibit 99.1 is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section, nor shall it be deemed incorporated by reference in any filing made by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise set forth herein or as shall be expressly set forth by specific reference in such a filing.

SUBMITTED HEREWITH:

Exhibit Number		Description
99.1		Press Release dated June 30,2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

		Biodexa Pharmaceuticals PLC
		(Registrant)
Date: June 30, 2026		/s/ Stephen Stamp
		Stephen Stamp
		Chief Executive Officer, Chief Financial Officer

EXHIBIT 99.1

Result of Annual General Meeting

June 30, 2026

Biodexa Pharmaceuticals PLC
(“Biodexa” or the “Company”)

Result of Annual General Meeting

Biodexa Pharmaceuticals PLC (Nasdaq: BDRX) (“Biodexa” or “the Company”), a clinical stage biopharmaceutical company developing innovative products focused on the treatment or prevention of gastrointestinal cancers announces that its re-scheduled Annual General Meeting held at 11.00 BST today, ordinary resolutions 1 through 7 passed with majorities of 94%, 73%, 92%, 81%, 81%, 91% and 94%, respectively. Ordinary resolution 8 and special resolution 10 failed to pass. Because resolution 11 was contingent on the passing of resolution 8, resolution 11 also failed to pass.

ENDS

About Biodexa Pharmaceuticals PLC

Biodexa Pharmaceuticals PLC (listed on NASDAQ: BDRX) is a clinical stage biopharmaceutical company developing a pipeline of innovative products for the treatment of diseases with unmet medical needs. The Company’s lead development programs include eRapa, under development for Familial Adenomatous Polyposis and Non-Muscle Invasive Bladder Cancer, MTX240 under development for Gastrointestinal Stromal Tumors (GIST) and tolimidone, under development for the treatment of type 1 diabetes.

eRapa is a proprietary oral capsule formulation of rapamycin, also known as sirolimus. Rapamycin is an mTOR (mammalian Target Of Rapamycin) inhibitor. mTOR has been shown to have a significant role in the signalling pathway that regulates cellular metabolism, growth and proliferation and is activated during tumorigenesis.

MTX240 is a molecular glue, bringing two intracellular proteins, PDE3a and SLFN12, specifically co-expressed by GIST cancer cells, into close proximity to form a stable complex. This interaction stabilizes SLFN12, enabling it to drive RNase-mediated apoptosis in GIST cells through a mechanism independent of KIT signalling.

Tolimidone is an orally delivered, potent and selective inhibitor of Lyn kinase. Lyn is a member of the Src family of protein tyrosine kinases, which is mainly expressed in hematopoietic cells, in neural tissues, liver, and adipose tissue. Tolimidone demonstrates glycaemic control via insulin sensitization in animal models of diabetes and has the potential to become a first in class blood glucose modulating agent.

Biodexa’s headquarters and R&D facility is in Cardiff, UK. For more information visit www.biodexapharma.com.

 Forward-Looking Statements
Certain statements in this announcement may constitute “forward-looking statements” within the meaning of legislation in the United Kingdom and/or United States. Such statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and are based on management’s belief or interpretation. All statements contained in this announcement that do not relate to matters of historical fact should be considered forward-looking statements. In certain cases, forward-looking statements can be identified by the use of words such as “plans”, “expects” or “does not anticipate”, or “believes”, or variations of such words and phrases or statements that certain actions, events or results “may”, “could”, “would”, “might” or “will be taken”, “occur” or “be achieved.” Forward-looking statements and information are subject to various known and unknown risks and uncertainties, many of which are beyond the ability of the Company to control or predict, that may cause their actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein.

Reference should be made to those documents that Biodexa shall file from time to time or announcements that may be made by Biodexa in accordance with the rules and regulations promulgated by the SEC, which contain and identify other important factors that could cause actual results to differ materially from those contained in any projections or forward-looking statements. These forward-looking statements speak only as of the date of this announcement. All subsequent written and oral forward-looking statements by or concerning Biodexa are expressly qualified in their entirety by the cautionary statements above. Except as may be required under relevant laws in the United States, Biodexa does not undertake any obligation to publicly update or revise any forward-looking statements because of new information, future events or events otherwise arising.

Filing Exhibits & Attachments

1 document

Press Releases

• EX-99.1 PRESS RELEASE 5.5 KB